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Treatment of primary cutaneous malignant melanoma has
traditionally been by wide and deep excision, since surgery is
the only curative treatment for this condition presently
available. Although the precise extent of surgery recom-
mended has varied, throughout most of this century the
approach has been radical for all cases. However, as our
understanding of the neoplastic process increases, treatment
modalities are being re-evaluated and different measures
adopted.
In 1907, Sampson Handley gave a Hunterian lecture on
the pathology of metastatic spread of melanoma in which he
suggested that the skin incision should be 'situated, as a rule
about an inch from the centre of the tumour'. He also
advocated the excision of subcutaneous fat, deep fascia and
muscle for a further two inches. From this recommendation
the standard policy of excision of melanoma with a 5 cm
margin of normal skin gradually evolved. More recently,
Petersen et al. (1962), in an effort to deal with the problems
of recurrence around the site of the original tumour,
advocated as much as a 15 cm clearance in certain cases. The
large experience of this Bristol group had a major effect on
British practice. However, the recognition by Breslow in 1970
that the simple measurement of tumour thickness was the
best indicator of prognosis in stage 1 cutaneous melanoma
carried the corollary that some melanomas carried an excel-
lent prognosis - almost in spite of treatment. This has led to
surgeons questioning the necessity of radical operations in all
cases, and opened the way to a more flexible management
policy (Breslow & Macht, 1977; Elder et al., 1983).
How wide an excision?
Breslow's work suggested that thin melanomas (<0.8 mm
thick) rarely recurred even with narrow excision margins, but
overall surgical acceptance was low. In 1983 Canadian
surgeons were surveyed, revealing that 63% of the polled
surgeons practised excision of 3 cm or more for thin
melanomas (Shelley et al., 1984). Much of the reluctance
related to the retrospective studies containing data requiring
cautious interpretation (Cascinelli et al., 1980; Schmoekel et
al., 1983). In 1985 the results of a 10-year prospective study
of selective excision margins for primary cutaneous malig-
nant melanoma demonstrated no deleterious effect on out-
come of this more conservative approach in terms of local or
regional recurrence. Three groups of melanoma were
identified on clinical assessment: impalpable, palpable but not
overtly nodular and nodular, which broadly fell into the
histological thickness ranges of <0.75 mm, 0.76-1.49 mm
and > 1.50 mm respectively. Treatment consisted of excision
with 1, 2 and 3 cm margins respectively (Taylor & Hughes,
1985).
In recent years further studies have been published which
confirm these findings. Zietels et al. (1988) reviewed 552
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patients with stage I cutaneous malignant melanoma treated
with a variety of resection margins. Their overall local recur-
rence rate was 1-4.5% and they observed no local recurrence
in lesions less than 1.40 mm thick with resection margins of
at least 1 cm. It must be noted, however, that within this
subgroup there were few patients with lesions between
1.00 mm and 1.40 mm thick and that there were significantly
different local recurrence rates for lesions greater than
1.0 mm thick with resection margins less than 2 cm (11.5%)
compared with margins greater than 2 cm (2.1%). Also of
note is that local recurrence still occurred with lesions more
than 2.0 mm thick despite excision margins of 3-4 cm.
A further study by Goldman and Byrd (1988) demon-
strated prospectively that in a series of 45 patients with
malignant melanomas less than 0.85 mm thick treated by
excision with margins no greater than 2 cm there were no
instances of recurrence or dissemination noted after a median
follow-up of 36 months. In a randomised prospective study
designed to evaluate the efficacy of a narrow excision margin
(1 cm) versus a wide excision margin (at least 3 cm) in stage 1
melanomas no thicker than 2.0 mm. Veronesi et al. (1988)
demonstrated that the narrow excision was as effective as the
wider excision. Local recurrence was not noted in the wide
excision group and was 0.9% in the other. Regional lymph
node metastases and distant metastases appeared at similar
rates: 4.6% and 2.3% in the 1 cm excision group respectively
compared with 6.5% and 2.6% in the 3 cm excision group.
From these series a consensus emerged which is in line
with the findings of the earlier study (Taylor & Hughes,
1985). With thin lesions (those impalpable or less than 1 mm
thick) local recurrence is rare provided exicision is complete.
A I cm margin is adequate to ensure this. A 2 cm margin is
adequate for horizontal growth phase melanomas more than
I mm thick. Overtly nodular melanomas will show some
local recurrence no matter how wide the excision margin.
This is an expression of aggressive tumour biology and there
is no evidence that very wide excision margins provide an
advantage over 3 cm clearance.
Much interest in the past has been directed to the depth of
excision, in particular whether or not the deep fascia should
be removed. No clear answer has emerged, particularly
because the anatomy of fascia varies in different parts of the
body and the thickness of subcutaneous fat varies widely.
The local recurrence rates from a number of studies, and that
in our own experience, suggest that a good clearance in depth
of subcutaneous fat beneath the melanoma is the important
factor. We remove the deep fascia in thin patients where it is
anatomically possible, but are satisfied with a 1-2 cm depth
of subcutaneous fat beneath the melanoma in more obese
subjects.
Special considerations apply in the head and neck and the
foot. Optimal clearance, both in width and depth, is often
impossible in the head and neck, yet local recurrence is not
notably greater than for other sites (Griffiths & Briggs, 1986),
reflecting the higher incidence of thin lesions in this site. In
our experience uncontrolled local recurrence is a greater
problem in this region when aggressive nodular lesions can-
not be removed widely. The same general principles apply to
melanoma of the foot, although digital lesions generally need
local amputation (Hughes et al., 1985).
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The quest for better cosmesis
While cure is the greatest concern of most cancer patients,
the final cosmetic result is their second concern, and due
consideration must be given when planning treatment.
Obviously, melanomas of the head and neck are most impor-
tant in this respect and some surgeons continue to insist on
skin grafting all excision defects. The justification for this has
been that full thickness flaps might hide local recurrences. In
fact, local recurrence is easier to detect beneath a supple flap
than an indurated partial thickness graft and the biological
implications of local recurrence mean that there is no great
advantage in early detection. Rotation flaps give a notably
superior cosmetic result and most facial and neck excisions
are suitable. In our own series, only eight of 53 patients
required skin grafts and these were usually in the scalp or
temple where they could be hidden by appropriate hair style.
Despite the increasing acceptance of narrower excision
margins considerable defects are still created by 2 or 3 cm
clearance of thicker melanomas. The cosmetic results of a
split skin graft are clearly inferior to those of primary
closure. Utilising the ability of monofilament prolene
material to slide freely through tissues it is possible to
achieve a higher proportion of primary closures. A prospec-
tive study of a multilayer, subcutaneous and subcuticular
prolene suture technique for primary closure demonstrated a
reversal of the ratio of wounds requiring grafting to primary
suture, with a 50% increase in the number of wounds being
dealt with by primary suture (Pritchard et al., 1988). Further-
more, the observed complication rate was significantly lower
in patients treated by primary suture than those grafted.
Two, three or four (depending on the depth of subcutaneous
fat) continuous prolene sutures are placed in the sub-
cutaneous and subcuticular layers while the wound is open.
The edges are approximated by pulling on all sutures slowly
and simultaneously so that the tension is applied simul-
taneously to all tissue sites, with uniform distribution
throughout the wound.
Rotation flaps have also been advocated on the trunk and
limbs for defects too large for primary closure but cosmetic
results are usually inferior to those achieved on the face.
Furthermore, technical failure may result in a much larger
defect than that obtained from skin grafting.
Adjuvant therapy
While the overall long-term results of treatment of primary
melanomas are very encouraging, with 60-70% 10-year sur-
vival (Taylor et al., 1984; McCarthy et al., 1985a), the good
prognosis relates to thin lesions and those more than 1.7 mm
thick fare much worse. Attempts to improve results with
adjuvant therapy have been disappointing in terms of local
recurrence and long-term cure.
Preoperative radiotherapy and adjuvant systemic
chemotherapy have been tried, the latter extensively, but no
benefit has been demonstrated as yet from properly con-
trolled trials (Hill et al., 1981; Creagan et al., 1978). This is
not surprising since melanoma is resistant to both modalities
of treatment in conventional dosage.
Greater interest and controversy has been aroused by the
advocates of adjuvant isolated limb perfusion in poor prog-
nosis melanoma of the limbs. When conducted by a suitably
trained and motivated team it is associated with negligible
morbidity and mortality. Tissue hyperthermia is necessary to
obtain optimal anti-tumour effect but unfortunately there is
no agreement on the precise degree of hyperthermia
associated with most benefit and least toxicity.
In many centres in the USA it is used routinely for all but
the thinnest melanomas and it has been advocated and used
in the Netherlands and Germany. Can its routine use in the
adjuvant situation by justified? The literature on the subject
is conflicting, with confusion compounded by studies employ-
ing historical controls which have not adequately accounted
for important prognostic factors. Two interesting studies
have come from Groningen in the Netherlands. In 1986 they
reported the results of a retrospective study comparing
patients with a melanoma> 1.5 mm thick who had had an
adjuvant limb perfusion in the Netherlands with a non-
perfused group in Sydney, Australia (Martijn et al., 1986).
They demonstrated a benefit from adjuvant limb perfusion in
a sub-group consisting of female patients with malignant
melanoma of the leg, excluding the foot, with decreased
locoregional recurrence rates and increased 10-year survival
and disease-free interval. However, when these same patients
were compared with patients from a geographically similar
area (Westphalia) no favourable effect of adjuvant limb per-
fusion was demonstrable (Franklin et al., 1988).
Recently Krige et al. (1988) have also shown good
locoregional control using melphalan in stage 1 melanoma,
but to date only one prospective randomised study (Ghussen
et al., 1988) has demonstrated a significant benefit. However,
this study was a small one and there was an exceptionally
high incidence of local recurrence in the control group. The
situation remains very much up in the air and it is important
that it is resolved by a large properly controlled trial. At least
three are currently underway, but progress seems slow and
much more in the way of resources may be needed to carry
such a trial to a successful conclusion.
A great deal of controversy still surrounds the debate on
the role of adjuvant lymph node dissection. Clearly not all
patients with melanoma would benefit from adjuvant lymph
node dissection, proponents have therefore concentrated on a
group of patients with intermediate thickness melanomas
(1.5-4 mm) who have a high chance of harbouring occult
lymph node metastases, without an overwhelming likelihood
of distant metastases.
McCarthy et al. (1985b) demonstrated a more than 40%
improvement in survival rate in over 2,000 patients with
melanomas between 1.6 and 3.00 mm thick and Balch et al.
(1982) reported a similar experience. These results must,
however, be interpreted with caution due to a lack of random
assignation of treatment and subsequent disparate numbers
in certain groups.
In an effort to resolve the controversies arising from such
studies two prospective trials of adjuvant lymph node dissec-
tion in stage 1 melanoma have been performed. The World
Health Organization Melanoma Group studied 553 patients
with stage 1 primary melanoma of the distal two-thirds of
the limbs, without benefit to survival from prophylactic
dissection (Veronesi et al., 1977, 1982). A further study of
171 patients with stage 1 melanoma of the extremities con-
ducted in the Mayo Clinic gave the same result (Sim et al.,
1986). Despite the careful design of these two studies a
number of sustainable objections have been raised (Balch et
al., 1985), leaving the efficacy of adjuvant lymph node dissec-
tion in selected melanoma patients an issue still to be
resolved by ongoing trials.
Much optimism has been aroused by the possibility of
various biological approaches to adjuvant therapy, including
unsaturated fatty acid supplementation and therapy with
biological response modifiers such as interferons or
interleukin. At present there is no hard evidence to support
this optimism.
References
BALCH, C.M., CASCINELLI, N., MILTON, G.W. & SIM, F.H. (1985).
Elective lymph node dissection: pros and cons. In Cutaneous
Melanoma: Clinical Management and Treatment Results World-
wide, Balch, C.M. & Milton, G.W. (eds) p. 131. Lippincott:
Philadelphia.
BALCH, C.M., SOONG, S.-J., MILTON, G.W. & 5 others (1982). A
comparison of prognostic factors and surgical results in 1, 786
patients with localised (stage 1) melanoma treated in Alabama,
USA and New South Wales, Australia. Ann Surg., 196, 677.194 G.T. NEADES & L.E. HUGHES
BRESLOW, A. (1970). Cross-sectional areas and depths of invasion in
the prognosis of cutaneous melanoma. Ann. Surg., 172, 902.
BRESLOW, A. & MACHT, S.D. (1977). Optimal size of resection mar-
gin for thin cutaneous melanoma. Surg. Gynecol. Obstet., 145,
691.
CASCINELLI, N., VAN DER ESCH, E.P., BRESLOW, A. MORABITO, A.
& BUFFALINO, R. (1980). Stage I melanoma of the skin: the
problems of resection margins. Eur. J. Cancer, 16, 1079.
CREAGAN, E.T., CUPPS, R.E., IVINS, J.C. & 4 others (1978). Adjuvant
radiation therapy for regional nodal metastases from malignant
melanoma: a randomised, prospective study Cancer, 42, 2206.
ELDER, D.E., GUERRY, D., HEIBERGER, R.M. & 6 others (1983).
Optimal resection margin for cutaneous malignant melanoma.
Plast. Reconstr. Surg., 71, 66.
FRANKLIN, H.R., SCHRAFFORDT KOOPS, H., OLDHOFF, J. & 11
others (1988). To perfuse or not the perfuse? A retrospective
comparative study to evaluate the effect of adjuvant isolated
regional perfusion in patients with stage I extremity melanoma
with a thickness of 1.5 mm or greater. J. Clin. Oncol., 6, 701.
GHUSSEN, F., KRUGER, I., GROTH, W. & STUTZER, H. (1988). The
role of regional hyperthermic cytostatic perfusion in the treat-
ment of extremity melanoma. Cancer, 61, 654.
GOLDMAN, L.I. & BYRD, R. (1988). Narrowing resection margins for
patients with low-risk melanoma. Am. J. Surg., 155, 242.
GRIFFITHS, R.W. & BRIGGS, J.C. (1986). Incidence of locally meta-
static ('recurrent') cutaneous malignant melanoma following con-
ventional wide margin excisional surgery of invasive clinical Stage
I tumours: importance of maximal primary tumour thickness. Br.
J. Surg., 73, 349.
HANDLEY, W.S. (1907). The pathology of melanotic growths in
relation to their operative treatment. Lancet, i, 927 and 996.
HILL, G.J. II, MOSS, S.E., GOLOMB, F. M. & 4 others (1981), DTIC
and combination therapy for melanoma: III. DTIC (NSC 45388).
Surgical Adjuvant Study COG Protocol 7040. Cancer, 47, 2256.
HUGHES, L.E., HORGAN, K., TAYLOR, B.A & LAIDLER, P. (1985).
Malignant melanoma of the hand and foot diagnosis and man-
agement. Br. J. Surg., 72, 811.
KRIGE, J.E.J., KING, H.S. & STROVER, R.M. (1988). Propylactic
hyperthermic limb perfusion in stage I melanoma. Eur. J. Surg.
Oncol., 14, 321.
MCCARTHY, W.H., SHAW, H.M., MILTON, G.W. & MCGOVERN, V.J.
(1985a). Melanoma in New South Wales, Australia. Experience
at the Sydney Melanoma Unit. In Cutaneous Melanoma: Clinical
Management and Treatment Results Worldwide, Balch, C.M. &
Milton, G.W. (eds) p. 371. Lippincott: Philadelphia.
MCCARTHY, W.H., SHAW, H.M. & MILTON, G.W. (1985b). Efficacy of
elective node dissection in 2,347 patients with clinical stage I
malignant melanoma. Surg. Gynecol. Obstet., 16, 575.
MARTIJN, H., SCHRAFFORDT KOOPS, H., MILTON, G.W. & 4 others
(1986). Comparison of two methods of treating primary malig-
nant melanoma Clark IV and V, thickness 1.5 mm and greater,
localised on the exttremities. Cancer, 57, 1923.
PETERSEN, N.C., BODENHAM, D.C. & LLOYD, O.C. (1962). Malig-
nant melanomas of the skin. A study of the origin, development,
aetiology, spread, treatment and prognosis. Br. J. Plast. Surg.,
15, 97.
PRITCHARD, G.A., ZHANG, L.J. & HUGHES, L.E. (1988). Suture or
graft? Changing trends in melanoma wound closure. Eur. J. Surg
Oncol., 14, 371.
SCHMOEKEL, C., BROCKELBRINK, A., BROCKELBRINK, H.,
KISTLER, H. & BRAUN-FALCO, 0. (1983). Low and high risk
malignant melanoma - III. Prognostic significance of the resec-
tion margin. Eur. J. Cancer Clin. Oncol., 19, 245.
SHELLEY, W., KERSEY, P., QUIRT, I. & PATER, J. (1984). Survey of
surgical management ofmalignant melanoma in Canada: optimal
margins of excision and lymph node dissection. Can. J. Surg., 27,
190.
SIM, F.H., TAYLOR, W.F., PRITCHARD, D.J. & SOULE, E.H. (1986).
Lymphadenectomy in management of stage I malignant
melanoma. A prospective randomised study. Mayo Clin. Proc., 6,
697.
TAYLOR, B.A. & HUGHES, L.E. (1985). A policy of selective excision
for primary cutaneous malignant melanoma. Eur. J. Surg. Oncol.,
11, 7.
TAYLOR, B.A., HUGHES, L.E. & WILLIAMS, G.T. (1984). Improving
prognosis for malignant melanoma in Britain. Br. J. Surg., 71,
950.
VERONESI, U., ADAMUS, J., BANDIERA, D.C. & 18 others (1977).
Inefficacy of immediate node dissection in stage I melanoma of
the limbs. N. Engl. J. Med., 297, 627.
VERONESI, U., ADAMUS, J., BANDIERA, D.C. & 18 others (1982).
Delayed regional lymph node dissection in stage I melanoma of
the skin of the lower extremities. Cancer, 49, 2420.
VERONESI, U., CASCINELLI, N., ADAMUS, J. & 29 others (1988).
This stage I primary cutaneous malignant melanoma. Com-
parison of excision with margins of I or 3 cm. N. Engl. J. Med.,
318, 1159.
ZEITELS, J., LA ROSSA, D., HAMILTON, R., SYNNESTVEDT, M. &
SCHULTZ, D. (1988). A comparison of local recurrence and resec-
tion margins of stage I primary cutaneous malignant melanomas.
Plast. Reconst. Surg., 81, 688.